Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Price effects of a hospital merger: Heterogeneity across health insurers, hospital products, and hospital locations.

Roos AF, Croes RR, Shestalova V, Varkevisser M, Schut FT.

Health Econ. 2019 Sep;28(9):1130-1145. doi: 10.1002/hec.3920. Epub 2019 Jul 1.

2.

Does managed competition constrain hospitals' contract prices? Evidence from the Netherlands.

Douven R, Burger M, Schut F.

Health Econ Policy Law. 2019 Apr 11:1-14. doi: 10.1017/S1744133119000215. [Epub ahead of print]

PMID:
30973119
3.

Who will become my co-residents? The role of attractiveness of institutional care in the changing demand for long-term care institutions.

Alders P, Deeg DJH, Schut FT.

Arch Gerontol Geriatr. 2019 Mar - Apr;81:91-97. doi: 10.1016/j.archger.2018.11.014. Epub 2018 Dec 1.

PMID:
30529804
4.

The Impact of Informal Caregiving for Older Adults on the Health of Various Types of Caregivers: A Systematic Review.

Bom J, Bakx P, Schut F, van Doorslaer E.

Gerontologist. 2018 Nov 3. doi: 10.1093/geront/gny137. [Epub ahead of print]

PMID:
30395200
5.

The 2015 long-term care reform in the Netherlands: Getting the financial incentives right?

Alders P, Schut FT.

Health Policy. 2019 Mar;123(3):312-316. doi: 10.1016/j.healthpol.2018.10.010. Epub 2018 Oct 16.

6.

Managed competition in the Netherlands: Do insurers have incentives to steer on quality?

Stolper KCF, Boonen LHHM, Schut FT, Varkevisser M.

Health Policy. 2019 Mar;123(3):293-299. doi: 10.1016/j.healthpol.2018.08.018. Epub 2018 Sep 6.

PMID:
30268584
7.

Value-based provider payment: towards a theoretically preferred design.

Cattel D, Eijkenaar F, Schut FT.

Health Econ Policy Law. 2018 Sep 27:1-19. doi: 10.1017/S1744133118000397. [Epub ahead of print]

PMID:
30259825
8.

Design and effects of outcome-based payment models in healthcare: a systematic review.

Vlaanderen FP, Tanke MA, Bloem BR, Faber MJ, Eijkenaar F, Schut FT, Jeurissen PPT.

Eur J Health Econ. 2019 Mar;20(2):217-232. doi: 10.1007/s10198-018-0989-8. Epub 2018 Jul 5.

9.

Trends in ageing and ageing-in-place and the future market for institutional care: scenarios and policy implications.

Alders P, Schut FT.

Health Econ Policy Law. 2019 Jan;14(1):82-100. doi: 10.1017/S1744133118000129. Epub 2018 May 21.

PMID:
29779497
10.

Can universal access be achieved in a voluntary private health insurance market? Dutch private insurers caught between competing logics.

Vonk RAA, Schut FT.

Health Econ Policy Law. 2019 Jul;14(3):315-336. doi: 10.1017/S1744133118000142. Epub 2018 May 7.

PMID:
29732999
11.

[Do healthcare insurers have too much power?]

Schut FT, Varkevisser M.

Ned Tijdschr Geneeskd. 2016;160:D1133. Dutch.

PMID:
28000577
12.

Competition policy for health care provision in the Netherlands.

Schut FT, Varkevisser M.

Health Policy. 2017 Feb;121(2):126-133. doi: 10.1016/j.healthpol.2016.11.002. Epub 2016 Nov 14.

PMID:
27923494
13.

What health plans do people prefer? The trade-off between premium and provider choice.

Determann D, Lambooij MS, de Bekker-Grob EW, Hayen AP, Varkevisser M, Schut FT, Wit GA.

Soc Sci Med. 2016 Sep;165:10-18. doi: 10.1016/j.socscimed.2016.07.022. Epub 2016 Jul 25.

PMID:
27485728
14.

Can universal access and competition in long-term care insurance be combined?

Bakx P, Schut F, van Doorslaer E.

Int J Health Econ Manag. 2015 Jun;15(2):185-213. Epub 2015 Jan 30.

15.

Switching health insurers: the role of price, quality and consumer information search.

Boonen LH, Laske-Aldershof T, Schut FT.

Eur J Health Econ. 2016 Apr;17(3):339-53. doi: 10.1007/s10198-015-0681-1. Epub 2015 Mar 28.

16.

Demand-side strategies to deal with moral hazard in public insurance for long-term care.

Bakx P, Chernichovsky D, Paolucci F, Schokkaert E, Trottmann M, Wasem J, Schut F.

J Health Serv Res Policy. 2015 Jul;20(3):170-6. doi: 10.1177/1355819615575080. Epub 2015 Mar 12.

PMID:
25770020
17.

Going formal or informal, who cares? The influence of public long-term care insurance.

Bakx P, de Meijer C, Schut F, van Doorslaer E.

Health Econ. 2015 Jun;24(6):631-43. doi: 10.1002/hec.3050. Epub 2014 Apr 8.

PMID:
24711082
18.

Tackling hospital waiting times: the impact of past and current policies in the Netherlands.

Schut FT, Varkevisser M.

Health Policy. 2013 Nov;113(1-2):127-33. doi: 10.1016/j.healthpol.2013.05.003. Epub 2013 Jun 6.

PMID:
23746931
19.

Preconditions for efficiency and affordability in competitive healthcare markets: are they fulfilled in Belgium, Germany, Israel, the Netherlands and Switzerland?

van de Ven WP, Beck K, Buchner F, Schokkaert E, Schut FT, Shmueli A, Wasem J.

Health Policy. 2013 Mar;109(3):226-45. doi: 10.1016/j.healthpol.2013.01.002. Epub 2013 Feb 8. Review.

PMID:
23399042
20.

Do patients choose hospitals with high quality ratings? Empirical evidence from the market for angioplasty in the Netherlands.

Varkevisser M, van der Geest SA, Schut FT.

J Health Econ. 2012 Mar;31(2):371-8. doi: 10.1016/j.jhealeco.2012.02.001. Epub 2012 Feb 10.

PMID:
22425770
21.

The impact of geographic market definition on the stringency of hospital merger control in Germany and the Netherlands.

Varkevisser M, Schut FT.

Health Econ Policy Law. 2012 Jul;7(3):363-81. doi: 10.1017/S1744133112000011. Epub 2012 Feb 21.

PMID:
22348390
22.

Early results from adoption of bundled payment for diabetes care in the Netherlands show improvement in care coordination.

de Bakker DH, Struijs JN, Baan CB, Raams J, de Wildt JE, Vrijhoef HJ, Schut FT.

Health Aff (Millwood). 2012 Feb;31(2):426-33. doi: 10.1377/hlthaff.2011.0912.

PMID:
22323174
23.

Pricing behaviour of nonprofit insurers in a weakly competitive social health insurance market.

Douven RC, Schut FT.

J Health Econ. 2011 Mar;30(2):439-49. doi: 10.1016/j.jhealeco.2010.12.006. Epub 2011 Jan 13.

PMID:
21295365
24.

Managed competition in the Dutch health system: is there a realistic alternative?

Schut FT, van de Ven WP.

Health Econ Policy Law. 2011 Jan;6(1):135-7. doi: 10.1017/S1744133110000393. No abstract available.

PMID:
21269529
25.

Effects of purchaser competition in the Dutch health system: is the glass half full or half empty?

Schut FT, van de Ven WP.

Health Econ Policy Law. 2011 Jan;6(1):109-23. doi: 10.1017/S1744133110000381.

PMID:
21269527
26.

Health care reform in the Netherlands: the fairest of all?

Schut F, van de Ven W.

J Health Serv Res Policy. 2011 Jan;16(1):3-4. doi: 10.1258/jhsrp.2010.010158. No abstract available.

PMID:
21186316
27.

Preferred providers and the credible commitment problem in health insurance: first experiences with the implementation of managed competition in the Dutch health care system.

Boonen LH, Schut FT.

Health Econ Policy Law. 2011 Apr;6(2):219-35. doi: 10.1017/S1744133110000320. Epub 2010 Dec 2.

PMID:
21122187
28.

Channeling consumers to preferred providers and the impact of status quo bias: does type of provider matter?

Boonen LH, Donkers B, Schut FT.

Health Serv Res. 2011 Apr;46(2):510-30. doi: 10.1111/j.1475-6773.2010.01196.x. Epub 2010 Oct 28.

29.

Spillover effects of supplementary on basic health insurance: evidence from The Netherlands.

Roos AF, Schut FT.

Eur J Health Econ. 2012 Feb;13(1):51-62. doi: 10.1007/s10198-010-0279-6. Epub 2010 Sep 23.

30.

Pharmaceutical policy in the Netherlands: from price regulation towards managed competition.

Boonen LH, van der Geest SA, Schut FT, Varkevisser M.

Adv Health Econ Health Serv Res. 2010;22:53-76. Review.

PMID:
20575228
31.

Assessing hospital competition when prices don't matter to patients: the use of time-elasticities.

Varkevisser M, van der Geest SA, Schut FT.

Int J Health Care Finance Econ. 2010 Mar;10(1):43-60. doi: 10.1007/s10754-009-9070-6. Epub 2009 Aug 7.

PMID:
19662527
32.

Which preferred providers are really preferred? Effectiveness of insurers' channeling incentives on pharmacy choice.

Boonen LH, Schut FT, Donkers B, Koolman X.

Int J Health Care Finance Econ. 2009 Dec;9(4):347-66. doi: 10.1007/s10754-009-9055-5. Epub 2009 Feb 26.

PMID:
19242791
33.

Some pain, no gain: experiences with the no-claim rebate in the Dutch health care system.

Holland J, Van Exel NJ, Schut FT, Brouwer WB.

Health Econ Policy Law. 2009 Oct;4(Pt 4):405-24. doi: 10.1017/S1744133109004861. Epub 2009 Feb 25.

PMID:
19239729
34.

Managed competition in the Netherlands: still work-in-progress.

Van de Ven WP, Schut FT.

Health Econ. 2009 Mar;18(3):253-5. doi: 10.1002/hec.1446. No abstract available.

PMID:
19206093
35.

Defining hospital markets for antitrust enforcement: new approaches and their applicability to The Netherlands.

Varkevisser M, Capps CS, Schut FT.

Health Econ Policy Law. 2008 Jan;3(Pt 1):7-29. doi: 10.1017/S1744133107004331.

PMID:
18634630
36.

Universal mandatory health insurance in the Netherlands: a model for the United States?

van de Ven WP, Schut FT.

Health Aff (Millwood). 2008 May-Jun;27(3):771-81. doi: 10.1377/hlthaff.27.3.771.

PMID:
18474971
37.

Preferences and choices for care and health insurance.

van den Berg B, Van Dommelen P, Stam P, Laske-Aldershof T, Buchmueller T, Schut FT.

Soc Sci Med. 2008 Jun;66(12):2448-59. doi: 10.1016/j.socscimed.2008.02.021. Epub 2008 Apr 8.

PMID:
18400349
38.
39.

Rationing and competition in the Dutch health-care system.

Schut FT, Van de Ven WP.

Health Econ. 2005 Sep;14(Suppl 1):S59-74. Review.

PMID:
16161190
40.

Market-oriented health care reforms and policy learning in the Netherlands.

Helderman JK, Schut FT, van der Grinten TE, van de Ven WP.

J Health Polit Policy Law. 2005 Feb-Apr;30(1-2):189-209.

PMID:
15943393
41.

Consumer price sensitivity and social health insurer choice in Germany and The Netherlands.

Schut FT, Gress S, Wasem J.

Int J Health Care Finance Econ. 2003 Jun;3(2):117-38.

PMID:
14626009
42.

Managed competition and consumer price sensitivity in social health insurance.

Schut FT, Hassink WH.

J Health Econ. 2002 Nov;21(6):1009-29.

PMID:
12475123
43.
44.
45.

A molecular view of the intestinal ecosystem.

Vaughan EE, Schut F, Heilig HG, Zoetendal EG, de Vos WM, Akkermans AD.

Curr Issues Intest Microbiol. 2000 Mar;1(1):1-12. Review.

PMID:
11709849
46.

Sphingomonas alaskensis sp. nov., a dominant bacterium from a marine oligotrophic environment.

Vancanneyt M, Schut F, Snauwaert C, Goris J, Swings J, Gottschal JC.

Int J Syst Evol Microbiol. 2001 Jan;51(Pt 1):73-9.

PMID:
11211276
47.

Belgium and The Netherlands revisited.

van Doorslaer E, Schut FT.

J Health Polit Policy Law. 2000 Oct;25(5):875-87. No abstract available.

PMID:
11068731
48.
49.

Towards a reinforced agency role of health insurers in Belgium and The Netherlands.

Schut FT, van Doorslaer EK.

Health Policy. 1999 Jul;48(1):47-67.

PMID:
10539585
50.

Priority care for employees: a blessing in disguise?

Brouwer WB, Schut FT.

Health Econ. 1999 Feb;8(1):65-73. Review.

PMID:
10082144

Supplemental Content

Support Center